Tafazzin knockdown causes hypertrophy of neonatal ventricular myocytes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 1, 2010, Pages

  He, Quan ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Adenosine 5 triphosphate; Cardiolipin; Dilated cardiomyopathy

Indexed keywords

ADENOVIRUS VECTOR; MITOCHONDRIAL PROTEIN; PROTEIN TAFAZZIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CONGESTIVE CARDIOMYOPATHY; GENE EXPRESSION; GENE SEQUENCE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ADENOSINE TRIPHOSPHATE; ADENOVIRIDAE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANIMALS, NEWBORN; CARDIOLIPINS; CARDIOMEGALY; CELLS, CULTURED; ENERGY METABOLISM; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HEART VENTRICLES; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 77953769776     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00098.2010     Document Type: Article

References (56)

1. Adiga IK, Nair RR. Multiple signaling pathways coordinately mediate reactive oxygen species dependent cardiomyocyte hypertrophy. Cell Biochem Funct 26: 346-351, 2008.
2. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 19: 263-268, 2003.
3. Bakker SJ, Leunissen KM. Hypothesis on cellular ATP depletion and adenosine release as causes of heart failure and vasodilatation in cardiovascular beriberi. Med Hypotheses 45: 265-267, 1995.
4. Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vaz FM, Wanders RJ. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet A 126A: 349-354, 2004.
5. Barth PG, Wanders RJ, Vreken P, Janssen EA, Lam J, Baas F. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome) (MIM 302060). J Inherit Metab Dis 22: 555-567, 1999. (Pubitemid 29281043)
6. Bianchi P, Pimentel DR, Murphy MP, Colucci WS, Parini A. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptorin-dependent ROS generation. FASEB J 19: 641-643, 2005.
7. Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5 is responsible for Barth syndrome. Nat Genet 12: 385-389, 1996.
8. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10: 1215-1220, 2001.
9. Cheng TH, Liu JC, Lin H, Shih NL, Chen YL, Huang MT, Chan P, Cheng CF, Chen JJ. Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 369: 239-244, 2004. (Pubitemid 38270782)
10. Cheng TH, Shih NL, Chen CH, Lin H, Liu JC, Chao HH, Liou JY, Chen YL, Tsai HW, Chen YS, Cheng CF, Chen JJ. Role of mitogen-activated protein kinase pathway in reactive oxygen species-mediated endothelin-1-induced beta-myosin heavy chain gene expression and cardiomyocyte hypertrophy. J Biomed Sci 12: 123-133, 2005.
11. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 292: C33-C44, 2007.
12. Claypool SM, Boontheung P, McCaffery JM, Loo JA, Koehler CM. The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome. Mol Biol Cell 19: 5143-5155, 2008.
13. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 115: 909-917, 2007.
14. Eble DM, Spinale FG. Contractile and cytoskeletal content, structure, and mRNA levels with tachycardia-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 268: H2426-H2439, 1995.
15. Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol 27: 849-856, 1995.
16. Goffart S, von Kleist-Retzow JC, Wiesner RJ. Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res 64: 198-207, 2004.
17. Greenberg ML, Lopes JM. Genetic regulation of phospholipid biosynthesis in Saccharomyces cerevisiae. Microbiol Rev 60: 1-20, 1996. (Pubitemid 26087760)
18. Gu Z, Valianpour F, Chen S, Vaz FM, Hakkaart GA, Wanders RJ, Greenberg ML. Aberrant cardiolipin metabolism in the yeast taz1 mutant: a model for Barth syndrome. Mol Microbiol 51: 149-158, 2004.
19. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 32, Suppl 4: S7-S12, 2008.
20. Harding P, Yang XP, Yang J, Shesely E, He Q, LaPointe MC. Gene expression profiling of dilated cardiomyopathy in older male EP4 knockout mice. Am J Physiol Heart Circ Physiol 298: H623-H632, 2010.
21. Harding P, Carretero OA, LaPointe MC. Effects of interleukin-1 beta and nitric oxide on cardiac myocytes. Hypertension 25: 421-430, 1995.
22. He Q, Greenberg ML. Post-translational regulation of phosphatidylglyc- erolphosphate synthase in response to inositol. Mol Microbiol 53: 1243-1249, 2004.
23. He Q, Harding P, LaPointe MC. PKA, Rap1, ERK1/2, and p90RSK mediate PGE2 and EP4 signaling in neonatal ventricular myocytes. Am J Physiol Heart Circ Physiol 298: H136-H143, 2010.
24. He Q, LaPointe MC. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 33: 283-289, 1999.
25. He Q, LaPointe MC. Src and Rac mediate endothelin-1 and lysophosphatidic acid stimulation of the human brain natriuretic peptide promoter. Hypertension 37: 478-484, 2001. (Pubitemid 32199015)
26. Heywood P. Evidence from serial sections that some cells contain large numbers of mitochondria. J Cell Sci 26: 1-8, 1977. (Pubitemid 8245091)
27. Higuchi Y, Otsu K, Nishida K, Hirotani S, Nakayama H, Yamaguchi O, Matsumura Y, Ueno H, Tada M, Hori M. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 34: 233-240, 2002.
28. Hwang S, Bohman R, Navas P, Norman JT, Bradley T, Fine LG. Hypertrophy of renal mitochondria. J Am Soc Nephrol 1: 822-827, 1990.
29. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 104: 12017-12022, 2007.
30. Jiang F, Ryan MT, Schlame M, Zhao M, Gu Z, Klingenberg M, Pfanner N, Greenberg ML. Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. J Biol Chem 275: 22387-22394, 2000.
31. Joshi AS, Zhou J, Gohil VM, Chen S, Greenberg ML. Cellular functions of cardiolipin in yeast. Biochim Biophys Acta 1793: 212-218, 2009.
32. Khuchua Z, Yue Z, Batts L, Strauss AW. A zebrafish model of human Barth syndrome reveals the essential role of tafazzin in cardiac development and function. Circ Res 99: 201-208, 2006.
33. LaPointe MC, Wu G, Garami M, Yang XP, Gardner DG. Tissuespecific expression of the human brain natriuretic peptide gene in cardiac myocytes. Hypertension 27: 715-722, 1996.
34. Ma L, Vaz FM, Gu Z, Wanders RJ, Greenberg ML. The human TAZ gene complements mitochondrial dysfunction in the yeast taz1Delta mutant. Implications for Barth syndrome. J Biol Chem 279: 44394-44399, 2004.
35. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113: 1807-1816, 2006.
36. McCutcheon LJ, Cory CR, Nowack L, Shen H, Mirsalami M, Lahucky R, Kovac L, O'Grady M, Horne R, O'Brien PJ. Respiratory chain defect of myocardial mitochondria in idiopathic dilated cardiomyopathy of Doberman pinscher dogs. Can J Physiol Pharmacol 70: 1529-1533, 1992.
37. Medeiros DM. Assessing mitochondria biogenesis. Methods 46: 288-294, 2008.
38. +-dependent malic enzyme. J Biol Chem 259: 6215-6221, 1984.
39. Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci USA 99: 1259-1263, 2002.
40. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 574: 33-39, 2006.
41. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 418: 261-275, 2009.
42. Saini-Chohan HK, Holmes MG, Chicco AJ, Taylor WA, Moore RL, McCune SA, Hickson-Bick DL, Hatch GM, Sparagna GC. Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J Lipid Res 50: 1600-1608, 2009.
43. Schlame M, Kelley RI, Feigenbaum A, Towbin JA, Heerdt PM, Schieble T, Wanders RJ, DiMauro S, Blanck TJ. Phospholipid abnormalities in children with Barth syndrome. J Am Coll Cardiol 42: 1994-1999, 2003.
44. Schlame M, Towbin JA, Heerdt PM, Jehle R, DiMauro S, Blanck TJ. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann Neurol 51: 634-637, 2002.
45. Spencer CT, Bryant RM, Day J, Gonzalez IL, Colan SD, Thompson WR, Berthy J, Redfearn SP, Byrne BJ. Cardiac and clinical phenotype in Barth syndrome. Pediatrics 118: e337-e346, 2006.
46. Urschel MR, O'Brien KM. High mitochondrial densities in the hearts of Antarctic icefishes are maintained by an increase in mitochondrial size rather than mitochondrial biogenesis. J Exp Biol 211: 2638-2646, 2008.
47. Valianpour F, Wanders RJ, Barth PG, Overmars H, van Gennip AH. Quantitative and compositional study of cardiolipin in platelets by electrospray ionization mass spectrometry: application for the identification of Barth syndrome patients. Clin Chem 48: 1390-1397, 2002. (Pubitemid 34925772)
48. Valianpour F, Wanders RJ, Overmars H, Vreken P, van Gennip AH, Baas F, Plecko B, Santer R, Becker K, Barth PG. Cardiolipin deficiency in X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM 302060): a study in cultured skin fibroblasts. J Pediatr 141: 729-733, 2002.
49. Vreken P, Valianpour F, Nijtmans LG, Grivell LA, Plecko B, Wanders RJ, Barth PG. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem Biophys Res Commun 279: 378-382, 2000.
50. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849-1865, 1991.
51. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270: 41-49, 1999.
52. Xu FP, Chen MS, Wang YZ, Yi Q, Lin SB, Chen AF, Luo JD. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 110: 1269-1275, 2004.
53. Xu Y, Condell M, Plesken H, Edelman-Novemsky I, Ma J, Ren M, Schlame M. A Drosophila model of Barth syndrome. Proc Natl Acad Sci USA 103: 11584-11588, 2006.
54. Xu Y, Malhotra A, Ren M, Schlame M. The enzymatic function of tafazzin. J Biol Chem 281: 39217-39224, 2006.
55. Xu Y, Sutachan JJ, Plesken H, Kelley RI, Schlame M. Characterization of lymphoblast mitochondria from patients with Barth syndrome. Lab Invest 85: 823-830, 2005.
56. Yen TY, Hwu WL, Chien YH, Wu MH, Lin MT, Tsao LY, Hsieh WS, Lee NC. Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review. Eur J Pediatr 167: 941-944, 2008.